EFFEKTIVNOST' RAMIPRILA V LEChENII I PROFILAKTIKE NEFROPATII U BOL'NYKh GIPERTONIChESKOY BOLEZN'Yu


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Article is devoted to the treatment and prevention of nephropathy in patients with arterial hypertension (AH). The problems of the pathogenesis of hypertensive nephroangiosclerosis and significance of activation of angiotensin-aldosterone system in its development and progression are discussed. General principles for the use of ACE inhibitors in these patients are presented. Researches on one of the drugs of this group - ramipril - are discussed in detail. The features of the pharmacokinetics and pharmacodynamics of this drug are described. The results of studies proving the effectiveness of ramipril in the treatment of nephropathy in different categories of patients are described in detail.

Full Text

Restricted Access

About the authors

L. O Minushkina

References

  1. Pontremoli R, Leoncini G, Ravera M, et al. Microalbuminuria, Cardiovascular, and Renal Risk in Primary Hypertension. J Am Soc Nephrol 2002, 13:169-72.
  2. Yuyun Mf, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study International J of Epidemiol 2004;33(1):189-98.
  3. Lydakis C, Lip GY. Microalbuminuria and cardiovascular risk. QJM 1998;91(6):381-91.
  4. Mann JF, Gerstein HC, Dulau-Florea I, et al. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int 2003;84(Suppl.): 192-96.
  5. Luke RG, Curtis JJ. Nephrosclerosis. In: Schrier RW and Gottschalk CW eds. Diseases of the Kidney. Fifth Edition, Vol. II. Boston. Little Brown and Co 1993:1433-50.
  6. Batuman V. Lead nephropathy, gout and hypertension. Am J MedSci 1993;305:241-47.
  7. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65(3):1009-16.
  8. Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996;18(4):658-70.
  9. Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in highrisk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104(5):522-26.
  10. Heinig RE. What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. Diabetes Obes Metab 2002;4(Suppl. 1):19-25.
  11. Mann JF, Gerstein HC, Yi QL. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol. 2003;14(3):641-47.
  12. Mann JF, Yi QL, Sleight P, Dagenais GR, et al. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin Nephrol 2005;63(3):181-87.
  13. Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352(9136):1252-56.
  14. Ruggenenti P, Perna A, Gherardi G, et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35(6):1155-65.
  15. Ruggenenti P, Perna A, Remuzzi G; et al. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001;12(12):2832-37.
  16. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365(9463):939-46.
  17. Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albu min: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328(7438):495.
  18. O'Hare JP, Bilous R, Mitchell T, et al. Low-Dose Ramipril Reduces Microalbuminuria in Type 1 Diabetic Patients Without Hypertension. Diabetes Care 2000;23:1823-29.
  19. Janickova ZD, Zavadova E, Kvapil M. The Effect of Ramipril Therapy on Cytokines and Parameters of Incipient Diabetic Nephropathy in Patients with Type 1 Diabetes. Mellitus. J of International Medical Research 2007; 35:374-83.
  20. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-31.
  21. Li PK, Chow KM, Wong TY, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003;139(2):105-12.
  22. Pisoni R, Ruggenenti P, Sangalli F, et al. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int 2002;62(3):1010-19.
  23. Ulusoy S, Ozkan G, Orem C, et al. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Ren Fail 2010;32(8):913-17.
  24. Gamboa JL, Pretorius M, Todd-Tzanetos DR, et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol 2012;23(2):334-42.
  25. Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16(2):474-81.
  26. Wuhl E, Trivelli A, Picca S, et al. ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009;361(17):1639-50.
  27. Wuhl E, Mehls O, Schaefer F. ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004;66(2):768-76.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies